Search details
1.
Interleukin-10 receptor signaling promotes the maintenance of a PD-1int TCF-1+ CD8+ T cell population that sustains anti-tumor immunity.
Immunity
; 54(12): 2825-2841.e10, 2021 12 14.
Article
in English
| MEDLINE | ID: mdl-34879221
2.
First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia.
N Engl J Med
; 388(19): 1739-1754, 2023 May 11.
Article
in English
| MEDLINE | ID: mdl-37163621
3.
Nucleosome repositioning in chronic lymphocytic leukemia.
Genome Res
; 33(10): 1649-1661, 2023 10.
Article
in English
| MEDLINE | ID: mdl-37699659
4.
Reassessing the chronic lymphocytic leukemia International Prognostic Index in the era of targeted therapies.
Blood
; 143(25): 2588-2598, 2024 Jun 20.
Article
in English
| MEDLINE | ID: mdl-38620092
5.
Acalabrutinib, venetoclax and obinutuzumab in relapsed CLL: Final efficacy and ctDNA analysis of the CLL2-BAAG trial.
Blood
; 2024 Apr 15.
Article
in English
| MEDLINE | ID: mdl-38620072
6.
T-bet suppresses proliferation of malignant B cells in chronic lymphocytic leukemia.
Blood
; 2024 Apr 29.
Article
in English
| MEDLINE | ID: mdl-38684038
7.
Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network.
Lancet
; 403(10441): 2293-2306, 2024 May 25.
Article
in English
| MEDLINE | ID: mdl-38705160
8.
The proto-oncogene TCL1A deregulates cell cycle and genomic stability in CLL.
Blood
; 141(12): 1425-1441, 2023 03 23.
Article
in English
| MEDLINE | ID: mdl-36179280
9.
Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial.
Blood
; 142(8): 687-699, 2023 08 24.
Article
in English
| MEDLINE | ID: mdl-37390310
10.
Final analysis of the CLL2-GIVe trial: obinutuzumab, ibrutinib, and venetoclax for untreated CLL with del(17p)/TP53mut.
Blood
; 142(11): 961-972, 2023 09 14.
Article
in English
| MEDLINE | ID: mdl-37363867
11.
Oncogenic role and target properties of the lysine-specific demethylase KDM1A in chronic lymphocytic leukemia.
Blood
; 142(1): 44-61, 2023 07 06.
Article
in English
| MEDLINE | ID: mdl-37023372
12.
High karyotypic complexity is an independent prognostic factor in patients with CLL treated with venetoclax combinations.
Blood
; 142(5): 446-459, 2023 08 03.
Article
in English
| MEDLINE | ID: mdl-37172204
13.
First-line venetoclax combinations versus chemoimmunotherapy in fit patients with chronic lymphocytic leukaemia (GAIA/CLL13): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial.
Lancet Oncol
; 25(6): 744-759, 2024 Jun.
Article
in English
| MEDLINE | ID: mdl-38821083
14.
Obinutuzumab (GA-101), ibrutinib, and venetoclax (GIVe) frontline treatment for high-risk chronic lymphocytic leukemia.
Blood
; 139(9): 1318-1329, 2022 03 03.
Article
in English
| MEDLINE | ID: mdl-35108374
15.
Evaluation of vecabrutinib as a model for noncovalent BTK/ITK inhibition for treatment of chronic lymphocytic leukemia.
Blood
; 139(6): 859-875, 2022 02 10.
Article
in English
| MEDLINE | ID: mdl-34662393
16.
The CLL12 trial: ibrutinib vs placebo in treatment-naïve, early-stage chronic lymphocytic leukemia.
Blood
; 139(2): 177-187, 2022 01 13.
Article
in English
| MEDLINE | ID: mdl-34758069
17.
Fludarabine, cyclophosphamide, and rituximab as first-line treatment in patients with chronic lymphocytic leukemia: A long-term analysis of the German CLL Study Group (GCLLSG) registry.
Eur J Haematol
; 2024 May 01.
Article
in English
| MEDLINE | ID: mdl-38693677
18.
Loss of ORP3 induces aneuploidy and promotes bladder cancer cell invasion through deregulated microtubule and actin dynamics.
Cell Mol Life Sci
; 80(10): 299, 2023 Sep 22.
Article
in English
| MEDLINE | ID: mdl-37740130
19.
Real-world experience among patients with relapsed/refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor failure in Europe: The SCHOLAR-2 retrospective chart review study.
Br J Haematol
; 202(4): 749-759, 2023 08.
Article
in English
| MEDLINE | ID: mdl-36257914
20.
Durable remissions following combined targeted therapy in patients with CLL harboring TP53 deletions and/or mutations.
Blood
; 138(19): 1805-1816, 2021 11 11.
Article
in English
| MEDLINE | ID: mdl-34086865